Imagion Biosystems Appendix 4C - Quarterly

Imagion Biosystems has today released its Appendix 4C Quarterly Cash Flow Report and update on Company activities for the quarter ending 31 December 2019. Read…


Appointment of Vice President Clinical & Regulatory Affairs

Imagion Biosystems announces the appointment of Dr Oliver Steinbach as Vice President of Clinical and Regulatory Affairs. Read the notice.


Response to ASX price query

Imagion Biosystems has today responded to a letter sent by the ASX on 31 December 2019, noting an increase in share price and trading volume. Read the response…


Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Imagion Biosystems has released "Notice Pursuant to Section 708A(5)(e) of the Corporations Act." Read the notice.


Appendix 3B

Imagion Biosystems has released Appendix 3B: New issue announcement, application for quotation of additional securities and agreement. Read Appendix 3B.


Change In Director's Interest Notice

Imagion Biosystems has released Change of Director's Interest Notices for David Ludvigson, Mark Van Asten, and Robert Proulx. Read the Change in Director's…


Form 604: Notice of change of interests of substantial holder

Imagion Biosystems Limited has released "Form 604: Notice of change of interests of substantial holder" to the market. Read Form 604.


Form 605: Notice of ceasing to be a substantial holder

Imagion Biosystems Limited has announced "Form 605: Notice of ceasing to be a substantial holder." Read Form 605.


Imagion Biosystems receives $300K order for supply of nanoparticles

Imagion Biosystems Limited announced the NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has placed an order totaling…


Completion of Renounceable Rights Issue

Imagion Biosystems has announced the successful completion of the renounceable rights issue raising approximately $3.6 million. Read Imagion Biosystems' Right…